On October 11, 2023, the U.S. Food and Drug Administration granted approval to Encorafenib (BRAF inhibitor) with Binimetinib (MEK inhibitor) for patients
Author: Saramshika Dhakal, MBBS Tribhuvan University Teaching Hospital, Kathmandu, Nepal. In a recent article published in JAMA Oncology (JAMA Oncol. 2023;9(4):465-472;
On September 26, the U.S. Food and Drug Administration expanded the approval of bosutinib (Bosulif) to include pediatric patients 1 year of
Presented by: Andrei Iagaru, MD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH.
Presented by: Pauline Funchain, M.D, Associate Professor of Medicine Stanford University, Stanford, CA. Covered by: Abdul Moiz Khan, M.D, Chief Fellow of
Presented by: Ulka Vaishampayan, M.D., Professor of Medicine/GU Oncology at University of Michigan School of Medicine, Ann Arbor, MI. Covered by: Abdul
Presented by: Arlene Siefker-Radtke, M.D, Professor of Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston,
Presented by: Russell K Pachynski M.D, Associate Professor and Director of GU Oncology Research at The Division of Oncology, Siteman Cancer Center
Presented by: Joel W Neal, MD. PhD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center,
Presented by: Millie Das, MD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH.